These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 38955031)
1. Alleviation effects of dexmedetomidine on myocardial ischemia/reperfusion injury through fatty acid metabolism pathway via Elovl6. Yuan H; Guo J; Wang C; Zhang C Int Immunopharmacol; 2024 Sep; 138():112588. PubMed ID: 38955031 [TBL] [Abstract][Full Text] [Related]
2. Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling. Yuan M; Meng XW; Ma J; Liu H; Song SY; Chen QC; Liu HY; Zhang J; Song N; Ji FH; Peng K Drug Des Devel Ther; 2019; 13():3137-3149. PubMed ID: 31564830 [TBL] [Abstract][Full Text] [Related]
3. Involvement of GPR30 in protection effect of Dexmedetomidine against myocardial ischemia/reperfusion injury in rat via AKT pathway. Shao Z; Shen Q; Kong M; Ni H; Hou X Acta Biochim Pol; 2021 Feb; 68(1):119-126. PubMed ID: 33629579 [TBL] [Abstract][Full Text] [Related]
4. Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro. Chang JH; Jin MM; Liu JT Biomed Pharmacother; 2020 Jul; 127():110188. PubMed ID: 32407987 [TBL] [Abstract][Full Text] [Related]
5. Dexmedetomidine Attenuates Myocardial Ischemia-Reperfusion Injury in Diabetes Mellitus by Inhibiting Endoplasmic Reticulum Stress. Li J; Zhao Y; Zhou N; Li L; Li K J Diabetes Res; 2019; 2019():7869318. PubMed ID: 31886285 [TBL] [Abstract][Full Text] [Related]
6. Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling. Yang FY; Zhang L; Zheng Y; Dong H Bioengineered; 2022 Jan; 13(1):1377-1387. PubMed ID: 34974801 [TBL] [Abstract][Full Text] [Related]
7. Dexmedetomidine Protects against Myocardial Ischemia/Reperfusion Injury by Ameliorating Oxidative Stress and Cell Apoptosis through the Trx1-Dependent Akt Pathway. Wu ZL; Davis JRJ; Zhu Y Biomed Res Int; 2020; 2020():8979270. PubMed ID: 33299886 [TBL] [Abstract][Full Text] [Related]
8. Dexmedetomidine protects H9C2 against hypoxia/reoxygenation injury through miR-208b-3p/Med13/Wnt signaling pathway axis. Wang Z; Yang Y; Xiong W; Zhou R; Song N; Liu L; Qian J Biomed Pharmacother; 2020 May; 125():110001. PubMed ID: 32070878 [TBL] [Abstract][Full Text] [Related]
9. Dexmedetomidine post-treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF-1α signalling. Peng K; Chen WR; Xia F; Liu H; Meng XW; Zhang J; Liu HY; Xia ZY; Ji FH J Cell Mol Med; 2020 Jan; 24(1):850-861. PubMed ID: 31680420 [TBL] [Abstract][Full Text] [Related]
10. Dexmedetomidine protects the heart against ischemia reperfusion injury via regulation of the bradykinin receptors. Song J; Du J; Tan X; Wu Z; Yuan J; Cong B Eur J Pharmacol; 2021 Nov; 911():174493. PubMed ID: 34506777 [TBL] [Abstract][Full Text] [Related]
11. Dexmedetomidine Attenuates Cellular Injury and Apoptosis in H9c2 Cardiomyocytes by Regulating p-38MAPK and Endoplasmic Reticulum Stress. Zhu Z; Ling X; Zhou H; Zhang C; Yan W Drug Des Devel Ther; 2020; 14():4231-4243. PubMed ID: 33116411 [TBL] [Abstract][Full Text] [Related]
12. Dexmedetomidine reversed hypoxia/reoxygenation injury-induced oxidative stress and endoplasmic reticulum stress-dependent apoptosis of cardiomyocytes via SIRT1/CHOP signaling pathway. Zhang Y; Zhao Q; Li X; Ji F Mol Cell Biochem; 2021 Jul; 476(7):2803-2812. PubMed ID: 33725228 [TBL] [Abstract][Full Text] [Related]
13. Dexmedetomidine Ameliorates Cardiac Ischemia/Reperfusion Injury by Enhancing Autophagy Through Activation of the AMPK/SIRT3 Pathway. He H; Liu P; Li P Drug Des Devel Ther; 2023; 17():3205-3218. PubMed ID: 37908314 [TBL] [Abstract][Full Text] [Related]
14. Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis. Wang L; Liu J; Wang Z; Qian X; Zhao Y; Wang Q; Dai N; Xie Y; Zeng W; Yang W; Bai X; Yang Y; Qian J Biomed Pharmacother; 2023 Sep; 165():115255. PubMed ID: 37549462 [TBL] [Abstract][Full Text] [Related]
15. Dexmedetomidine Attenuates Hypoxia/Reoxygenation Injury of H9C2 Myocardial Cells by Upregulating miR-146a Expression via the MAPK Signal Pathway. Chu Y; Teng J; Feng P; Liu H; Wang F; Wang H Pharmacology; 2022; 107(1-2):14-27. PubMed ID: 34718238 [TBL] [Abstract][Full Text] [Related]
16. Dexmedetomidine postconditioning suppresses myocardial ischemia/reperfusion injury by activating the SIRT1/mTOR axis. Zhang X; Li Y; Wang Y; Zhuang Y; Ren X; Yang K; Ma W; Zhong M Biosci Rep; 2020 May; 40(5):. PubMed ID: 32406910 [TBL] [Abstract][Full Text] [Related]
17. Dexmedetomidine alleviates Hypoxia/reoxygenation-induced mitochondrial dysfunction in cardiomyocytes via activation of Sirt3/Prdx3 pathway. Tan Q; Dong W; Wang Q; Gao L Daru; 2024 Jun; 32(1):189-196. PubMed ID: 38407745 [TBL] [Abstract][Full Text] [Related]
18. Dexmedetomidine protects cardiomyocytes against hypoxia/reoxygenation injury via multiple mechanisms. Cai S; Liu Y; Cheng Y; Yuan J; Fang J J Clin Lab Anal; 2022 Jul; 36(7):e24119. PubMed ID: 34882841 [TBL] [Abstract][Full Text] [Related]
19. Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats. Zhong Y; Li YP; Yin YQ; Hu BL; Gao H Int Immunopharmacol; 2020 Sep; 86():106768. PubMed ID: 32679539 [TBL] [Abstract][Full Text] [Related]
20. Dexmedetomidine alleviates myocardial ischemia-reperfusion injury by down-regulating miR-34b-3p to activate the Jagged1/Notch signaling pathway. Guo P; Yi H; Han M; Liu X; Chen K; Qing J; Yang F Int Immunopharmacol; 2023 Mar; 116():109766. PubMed ID: 36764271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]